Co-blockade of the T-cell immunoreceptor with Ig and ITIM domains – TIGIT, for short – is being widely studied as a way of widening the pool of candidates that could benefit from checkpoint inhibition, while potentially improving the efficacy of PD-1/PD-L1 monotherapy. However, initial enthusiasm that this strategy could prove fruitful has been subdued after disappointing findings released in 2022.
Will Anti-TIGITs Prove Their Value in 2023?
The promise of TIGIT as an oncology target in combination with PD-1/PD-L1 inhibitors has prompted an influx of investment into anti-TIGIT agents and five agents are already in advanced clinical trials. That initial enthusiasm has been dampened as of late, after disappointing Phase III data. Investors are hoping that 2023 will be the year that restores hope in the anti-TIGIT pipeline.
